Varian Announces First Participant Treated in GENESIS II Clinical Trial of Genicular Artery Embolization for Knee Osteoarthritis

PALO ALTO, Calif., Nov. 17, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, announced today that the first trial participant has been treated as part of GENESIS II (Genicular artEry embolisatioN in patiEnts with oSteoarthrItiS of the knee), a study of EmbozeneĀ® microspheres...

Click to view original post